Dong-A ST Receives US FDA Approval for Phase 3 Clinical Trial Plan of Chronic Psoriasis Treatment
[Asia Economy Reporter Minji Lee] Dong-A ST announced on the 25th that it has received approval from the U.S. Food and Drug Administration (FDA) for the Phase 3 clinical trial plan of ‘DMB-3115,’ a treatment for chronic plaque psoriasis.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Jeong Yu-kyung Is a Neighbor"...Itaewon Standalone House with Record 23.2 Billion Won Appraisal Up for Auction [Real Estate AtoZ]
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The company stated, “We plan to comparatively evaluate the efficacy, safety, and immunogenicity of ‘DMB-3115,’ a biosimilar of Stelara, a treatment for plaque psoriasis and psoriatic arthritis.”
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
